United States Food and Drug Administration (USFDA) has concluded general Good Manufacturing Practices (GMP) inspection at Piramal Pharma’s facility at Aurora, Canada. The inspection was conducted from May 26, 2025 to May 30, 2025.
The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation. The Company remains committed to maintain the highest standards of compliance.
Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
